Holen Sie sich die Stockscreener-App
59.02
0.51%
0.30
Vorhandelsmarkt:
59.51
0.49
+0.83%
Schlusskurs vom Vortag:
$58.72
Offen:
$58.6773
24-Stunden-Volumen:
2.16M
Relative Volume:
0.60
Marktkapitalisierung:
$26.16B
Einnahmen:
$2.44B
Nettoeinkommen (Verlust:
$1.36B
KGV:
30.91
EPS:
1.9093
Netto-Cashflow:
$574.14M
1W Leistung:
+0.84%
1M Leistung:
+6.63%
6M Leistung:
+46.09%
1J Leistung:
+63.90%
1-Tages-Spanne:
$58.36
$59.44
1-Wochen-Bereich:
$56.90
$59.44
52-Wochen-Spanne:
$34.08
$59.44
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
59.02 | 26.16B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
473.09 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
651.91 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.60 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.75 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
268.74 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
RPHC5035520 Bond Risk Profile - TradingView
RPHC5237354 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighShould You Buy? - MarketBeat
RPHC5237354 Bond Profile — Key Metrics - TradingView
RPHC5035520 Bond Coupon Profile — Rate & Payments - TradingView
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma - marketscreener.com
Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
177,500 Shares in Royalty Pharma PLC $RPRX Acquired by Andra AP fonden - MarketBeat
Press Release: Royalty Pharma Declares Third Quarter 2026 Dividend - 富途牛牛
RPHC6166013 Bond Risk Profile - TradingView
RPHC6166013 Bond Profile — Key Metrics - TradingView
Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com UK
Royalty Pharma PLC (RPRX) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com South Africa
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune - marketscreener.com
Royalty Pharma deal includes $125M upfront for heart antibody - Stock Titan
Royalty Pharma PLC $RPRX Shares Bought by Swiss National Bank - MarketBeat
Mediolanum International Funds Ltd Sells 40,296 Shares of Royalty Pharma PLC $RPRX - MarketBeat
SEB Asset Management AB Invests $12.97 Million in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc. - MarketBeat
How (RPRX) Movements Inform Risk Allocation Models - Stock Traders Daily
Hsbc Holdings PLC Acquires 1,486,020 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824521 Bond Profile — Key Metrics - TradingView
Royalty Pharma declares $0.235 dividend - MSN
US78081BAP8 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237916 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237916 Bond Profile — Key Metrics - TradingView
RPHC6166012 Bond Profile — Key Metrics - TradingView
RPHC6166012 Bond Risk Profile - TradingView
Royalty Pharma declares $0.235 quarterly dividend By Investing.com - Investing.com South Africa
Royalty Pharma declares $0.235 quarterly dividend - Investing.com UK
Royalty Pharma Maintains Quarterly Dividend at $0.235 a Share, Payable on Sept. 10 to Shareholders of Record on Aug. 14 - marketscreener.com
Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share - Quiver Quantitative
Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.6% Yield - StreetInsider
Royalty Pharma plc Declares Third Quarter 2026 Dividend, Payable on September 10, 2026 - marketscreener.com
Royalty Pharma stock hits all-time high at 58.85 USD By Investing.com - Investing.com South Africa
RPHC6166012 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month HighHere's Why - MarketBeat
Royalty Pharma stock hits all-time high at 58.85 USD - Investing.com
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
RPHC5824522 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma to announce Q2 2026 financial results on August 5 - scanx.trade
Royalty Pharma schedules 8 a.m. webcast for Aug. 5 results - Stock Titan
RPHC5222527 Bond Profile — Key Metrics - TradingView
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 - Yahoo Finance
US78081BAN3 Bond Coupon Profile — Rate & Payments - TradingView
US78081BAN3 Bond Risk Profile - TradingView
Royalty Pharma PLC $RPRX Shares Sold by J. Safra Sarasin Holding AG - MarketBeat
Calamos Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824522 Bond Risk Profile - TradingView
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Royalty Pharma Plc-Aktie (RPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.52 |
100,000 |
5,651,813 |
459,399 |
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.46 |
30,000 |
1,693,658 |
40,000 |
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):